Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
We Can Medicines Co's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for We Can Medicines Co's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 6 years, We Can Medicines Co's highest Yield on Cost was 0.87. The lowest was 0.00. And the median was 0.73.
ROCO:6929's 5-Year Yield-on-Cost % is not ranked *
in the Consumer Packaged Goods industry.
Industry Median: 3.395 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
We Can Medicines Co (ROCO:6929) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
We Can Medicines Co 5-Year Yield-on-Cost % Related Terms
ROCO:6929 vs KHC, GIS: 5-Year Yield-on-Cost % Comparison
For the Packaged Foods subindustry, We Can Medicines Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
We Can Medicines Co 5-Year Yield-on-Cost % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, We Can Medicines Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where We Can Medicines Co's 5-Year Yield-on-Cost % falls into.
We Can Medicines Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
We Can Medicines Co (ROCO:6929) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 12, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on We Can Medicines Co and its competitors. According to the industry distribution chart, We Can Medicines Co ranks #999999 out of 1164 companies in the Consumer Packaged Goods industry.
Is We Can Medicines Co's 5-Year Yield-on-Cost % too high?
We Can Medicines Co's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, We Can Medicines Co ranks #999999 out of 1164 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, We Can Medicines Co has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does We Can Medicines Co's 5-Year Yield-on-Cost % compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, We Can Medicines Co ranks #999999 out of 1164 companies for 5-Year Yield-on-Cost %. This places We Can Medicines Co in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 3.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Consumer Packaged Goods company?
The median 5-Year Yield-on-Cost % among Consumer Packaged Goods companies is 3.40, based on 1,164 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on We Can Medicines Co and its competitors. For the Consumer Packaged Goods industry, the median 5-Year Yield-on-Cost % is 3.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. We Can Medicines Co's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is We Can Medicines Co stock overvalued right now?
Based on GuruFocus' analysis, We Can Medicines Co (ROCO:6929) is currently considered Possible Value Trap. The stock's GF Value™ is NT$39.09, compared to a current price of NT$23.10 — trading 40.9% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. We Can Medicines Co's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For We Can Medicines Co (ROCO:6929), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is We Can Medicines Co (ROCO:6929) Overvalued in 2026?
Based on GuruFocus' analysis, We Can Medicines Co stock appears to be undervalued.
The current stock price of NT$23.10 is trading 40.9% below its estimated GF Value™ of NT$39.09.
GuruFocus considers We Can Medicines Co to be Possible Value Trap.
Key valuation signals for ROCO:6929:
5-Year Yield-on-Cost %: 0.00
GF Value™: NT$39.09 vs. price of NT$23.10 (40.9% below fair value)
No single metric tells the full story. See the ROCO:6929 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
We Can Medicines Co Ltd is a Taiwan-based company mainly engaged in the operation of chain cosmeceutical drugstores. The Company's main products include pharmaceuticals and health food, maternity and infant products, medical supplies, beauty cosmetics, and daily necessities.
46GF Score
Get the complete analysis for ROCO:6929
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6929 has been successfully added to your 
